Core Insights - The article highlights the presentation of real-world research data on NEFECON® (Budesonide Delayed-Release Capsules) at the 18th International IgA Nephropathy Symposium (IIgANN 2025) [1] - A significant observational study demonstrated the efficacy and safety of NEFECON® in treating IgA nephropathy over a 12-month period, confirming its substantial clinical benefits for long-term treatment [1] Company Insights - NEFECON® is showcased as a promising treatment option for IgA nephropathy, with data from multiple top hospitals in China [1] - The research emphasizes the importance of real-world evidence in supporting the clinical use of NEFECON® [1] Industry Insights - The presentation at the symposium indicates a growing interest in innovative treatments for IgA nephropathy within the nephrology field [1] - The findings may influence future treatment guidelines and patient management strategies for IgA nephropathy [1]
云顶新耀：耐赋康在“长期对因治疗”IgA肾病方面具有显著临床获益